Definition

An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor, with potential antineoplastic activity. Upon oral administration, PI3K inhibitor TL117 specifically inhibits the activity of PI3K, and prevents the activation of the PI3K/Akt (protein kinase B)-mediated signaling pathway. This may result in the inhibition of both tumor cell growth and survival in PI3K-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.